Research Vol. 33 — Natural Medicine vs. Pharma
How a trillion-dollar industry buried the medicine your grandmother already knew — and why the patent wall is the most powerful weapon in the arsenal.
In 1910, Abraham Flexner — a man with no medical degree — toured 155 medical schools across North America and issued a report that would eliminate every alternative to pharmaceutical medicine within a generation. Commissioned by the Carnegie Foundation and funded by John D. Rockefeller, the Flexner Report recommended closing nearly 80% of all medical programs: every homeopathic college, every naturopathic school, every eclectic therapy program. They weren't shut down because the science demanded it. They were shut down because the money demanded it.
Rockefeller poured at least $180 million into medical schools aligned with the biomedical model between 1910 and 1930. Not a single dollar went to a homeopathic college or hospital. By 1924, only 79 medical schools remained — down from 186. Only 2 of 7 Black medical schools survived. An entire ecosystem of healing traditions was dismantled in under 30 years.
"The AMA engaged in an unlawful conspiracy in restraint of trade to contain and eliminate the chiropractic profession."
Pharmaceutical and health products is the single most powerful lobbying sector in the United States — by a wide margin. In 2024, the industry spent $391.5 million on federal lobbying. Over the 20-year stretch from 1999 to 2018, the total was $4.7 billion in lobbying, plus $414 million to presidential and congressional candidates, plus $877 million to state-level campaigns. That's over $6 billion buying the people who write the rules about drugs.
There are 535 members of Congress. There are an estimated 1,451 to 1,834 registered pharmaceutical lobbyists — roughly three per lawmaker. And 61% of PhRMA's own lobbyists are revolving-door hires who previously held government positions.
The FDA is supposed to regulate pharmaceutical companies. But when the regulator and the regulated are the same rotating cast of people, the word "regulate" loses all meaning. The pattern is documented, specific, and ongoing.
| Name | FDA Role | Industry Landing | Time / Money |
|---|---|---|---|
| Scott Gottlieb | FDA Commissioner, 2017–2019 | Pfizer Board of Directors | 83 days after leaving / $330K+/yr |
| Mark McClellan | FDA Commissioner, 2002–2004 | Johnson & Johnson Board | $3.3M from J&J since 2013 |
| Stephen Ostroff | Acting Commissioner, 2015 | Pfizer consulting | $752,310 from Pfizer post-departure |
| Patrizia Cavazzoni | CDER Director | Pfizer Chief Medical Officer | Reviewed drugs she now helps sell |
A 2018 investigation by Science magazine tracked 16 FDA medical examiners across 28 drug approvals. Eleven of those 16 — 69% — subsequently went to work for or consult with the companies whose drugs they approved.
"Companies often hire agency staffers who managed their successful drug reviews."
The FDA's drug review operation is now primarily funded by the companies it regulates. Under the Prescription Drug User Fee Act (PDUFA), pharmaceutical companies pay application and product fees directly to the FDA. In 1993, those fees funded 7% of the review program's budget. By FY2025, they fund 77%.
A 2017 Yale/JAMA study tracked 222 drugs approved between 2001 and 2010. Nearly 1 in 3 — 71 drugs — had major safety issues post-approval: withdrawals, black-box warnings, or safety communications. This is the output of an accelerated, industry-funded review pipeline.
Rofecoxib (Vioxx) was on the market for 5 years before Merck pulled it in 2004. Estimated deaths: 38,000–55,000 Americans. Merck had data suggesting cardiovascular risk as early as 2000. Settlement: $4.85 billion. No criminal charges.
GlaxoSmithKline's diabetes drug showed a 43% increased heart attack risk. GSK paid $3 billion in the largest healthcare fraud settlement of its time. Avandia was never fully withdrawn — it remains available under restricted access in the U.S.
Natural compounds cannot be patented. A plant that grew in the ground for ten thousand years belongs to no one — which means no pharmaceutical company can spend $350 million running a Phase III trial on it, because every competitor could sell the same compound the day results came out. There is no return on investment. So the studies don't get funded. And the compounds get dismissed as "unproven."
This is not suppression in the conspiratorial sense. It is structural. The incentive simply does not exist. Meanwhile, pharma routinely isolates, modifies, and patents a synthetic version of the same molecule — then markets it as innovation. Aspirin came from willow bark. Metformin, the world's most-prescribed diabetes drug, derives from a medieval herbal remedy, Galega officinalis. Taxol, one of the most important cancer drugs ever developed, comes from Pacific yew bark. The source material was free. The patent is not.
| Drug (Patented) | Natural Origin | Drug Cost/Month | Natural Alternative/Month |
|---|---|---|---|
| Metformin (generic) | French lilac / Galega officinalis | $4–10 (generic) | Berberine: $10–30 |
| SSRIs (Prozac/generic) | — (synthetic) | $10–30/mo (generic) | St. John's Wort: $8–20 |
| NSAIDs (Celebrex) | Aspirin from willow bark | $180–250/mo (brand) | Curcumin: $15–40 |
| Statin drugs (brand) | Red yeast rice (lovastatin) | $250–400/mo (brand) | Red yeast rice: $15–30 |
| Anti-anxiety Rx | Valerian, Kava (traditional) | $50–200/mo (brand) | Ashwagandha: $10–25 |
Note: Generic pharmaceutical drugs are often cheaper than quality supplements. The cost argument is strongest against brand-name pricing and for uninsured patients. Always compare generics vs. generics.
The narrative that natural remedies are "unproven" is not accurate — it is underfunded. When clinical trials do happen, the results are often striking. The problem is they don't happen often enough, and the trials that do exist tend to be smaller and shorter than pharma-sponsored trials. Here is what the peer-reviewed literature actually shows.
Depression scores dropped from 23 to 8 in a Johns Hopkins psilocybin trial — an effect size roughly four times larger than traditional antidepressants. The FDA granted Breakthrough Therapy Designation. Zero approvals to date.
Adverse drug reactions are among the leading causes of death in America. A landmark JAMA meta-analysis estimated 106,000 Americans die annually from adverse drug reactions among hospitalized patients alone. More recent analyses suggest 250,000 to 300,000 deaths per year when all settings are included. The opioid crisis — manufactured by pharmaceutical companies, approved by the FDA, marketed by doctors who were paid to prescribe — has killed more than one million Americans since 1999.
Compare that to dietary supplements. The National Poison Data System documented 34 deaths total from dietary supplements over a 13-year period. Approximately 2.6 deaths per year. That is not a misprint.
The U.S. and New Zealand are the only two countries on Earth that permit direct-to-consumer prescription drug advertising. Pharma became the #2 overall U.S. ad spender in 2023, trailing only consumer packaged goods. In January–May 2024, pharmaceutical companies accounted for 24.4% of all evening ad minutes on major news networks — ABC, CBS, CNN, Fox News, MSNBC, NBC. Nearly half of all household TV ad impressions for prescription brands ran on those seven channels.
This is not a coincidence. News organizations that depend on pharma advertising for survival do not cover pharma the way they would cover any other beat. A 2023 Johns Hopkins study found that pharmaceutical ad spending disproportionately favors drugs with low added therapeutic benefit — the ones that need the most marketing to justify their price tags.
The American model — where natural medicine is either unregulated "food" or dismissed entirely — is the global exception, not the rule. Most of the world has developed frameworks for integrating traditional medicine into mainstream healthcare.
| Country / Region | Approach | Coverage / Scale |
|---|---|---|
| Germany | Commission E: 380 herbal monographs, herbal Rx covered by insurance | Doctors trained in phytotherapy can prescribe herbal medicines |
| Japan | 148 Kampo formulations + 241 crude drugs covered by national insurance | 80%+ of Japanese MDs currently prescribe Kampo medicines |
| India | Full Ministry of AYUSH; 26,636 primary health centers with Ayush services | FY2026 budget: ~$530M. WHO Global Centre for Traditional Medicine based in Gujarat |
| China | 2017 TCM Law: traditional medicine integrated into 90% of hospitals | Covered by national health insurance; equal legal status with biomedicine |
| EU | Directive 2004/24/EC: herbal medicines as medicinal products with pre-market authorization | GMP required; 30 years' traditional use documentation required for authorization |
90 of 106 WHO Member States now have national traditional medicine policies — up from just 25 in 1999. Approximately 80% of the global population uses traditional medicine at least occasionally. The U.S. remains structurally unable to integrate what the rest of the world already accepts.
While the medical establishment debates the legitimacy of alternative medicine, the American public has already voted with their wallets. Usage of complementary and alternative medicine has nearly doubled in 20 years. In 2022, 36.7% of American adults used at least one complementary health approach — up from 19.2% in 2002. Meditation is now practiced by 60.5 million Americans. Yoga has tripled in adoption. Americans spend $30.2 billion per year out-of-pocket on complementary health — because insurance won't cover it, and they're choosing it anyway.
The answer to pharma's problems is not to trust every supplement company selling you a miracle. Over 80,000 commercial supplement products exist in the U.S. market. Most are unstudied. Some are dangerous — contaminated bodybuilding products and concentrated green tea extracts account for 20% of U.S. hepatotoxicity cases. The supplement industry has its own grifters and the FDA does not require pre-market approval for safety or efficacy.
The path forward is not "pharma bad, herbs good." It is informed integration: know what the evidence actually shows, buy from verified suppliers, work with a practitioner who understands both systems, and understand that generic pharmaceutical drugs are sometimes the cheaper, better-studied option. What matters is access to the full range — not being forced into one lane because the other lane was buried under a century of lobbying.